Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Relapsed Small Cell Lung Cancer
NCT00022711Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Jan 2002
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in small cell lung cancer (SCLC), sponsored by Fox Chase Cancer Center. Primary endpoints: Response Rate and Safety. Started Jan 2002; status: completed.
02
Drugs
temozolomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00022711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00022711.